BioSpace News Archive

NeoGenomics, Inc. announced that its liquid biopsy focused subsidiary Inivata Limited has unveiled new data at the American Association for Cancer Research Annual Meeting further demonstrating the potential of its RaDaR assay for the detection of minimal residual disease and recurrence.

At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company (NYSE: LLY) announced today at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference.

POXEL SA (Euronext: POXEL - FR0012432516), is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PXL770 for the treatment of patients with adrenomyeloneuropathy (AMN), the most common form of X-linked adrenoleukodystrophy (ALD).

IDEXX Laboratories, Inc., a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2022 first quarter results for Wednesday, May 4, 2022 before the market opens.

Kintara Therapeutics, Inc. (NASDAQ: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that it has presented data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

Pulse oximeters are gaining immense traction across the globe as more and more people around the world are considering self-health assessment tests at home, especially during and after the pandemic

Jackson Center, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Halberd Corporation (OTC PINK: HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc.

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that an oral presentation and poster presentation for RBN-2397, the Company’s lead development candidate, was presented today, April 11, 2022, at the American Association for Cancer Research (AACR) Annual Meeting 2022 taking place in New Orleans, Louisiana.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted thirteen new employees options to purchase a total of 28,900 shares of the Company’s common stock at an exercise price per share of $33.70, which was the closing price on April 8, 2022, and restricted stock units to acquire a total of 14,450 shares of the Company’s common stock.

Jerusalem, Israel and Boca Raton, Florida--(Newsfile Corp. - April 11, 2022) - NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on the stem cell-based technology platform developed by 30%-owned, Israel-based NewStem Ltd., today announced NewStem’s filing of a pre-submission to the FDA for a De Novo Request and an in vitro diagnostic device (IVDD) for Europe, the Middle East and Africa (EMA) for their NewStem Software Diagnostic Device.